ScreenerHero
HIMSHims & Hers Health, Inc.
NYSE · US · Consumer Defensive · Drug Manufacturers - Specialty & Generic · hims.com
32.40USD+4.20%Mkt Cap: 7.25B $P/E: —

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of I…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.47BUSDP/E 37.4

Key Statistics

Company
Market Cap7.25B $
Enterprise Value8.14B $
Revenue (TTM)2.58B $
Gross Profit1.73B $
Net Income (TTM)128.37M $
Revenue/Share11.29 USD
Last Price32.40 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.4K
CountryUS
SectorConsumer Defensive
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)28.59
PEG2.15
EV/EBITDA-799.70
EV/Revenue3.16
P/S2.88
P/B22.94
EPS (TTM)-0.66
EPS (Forward)1.11
52W Range
13.7436% of range65.30
52W High65.30 USD
52W Low13.74 USD
Profitability
Gross Margin73.84%
Oper. Margin-12.75%
EBITDA Margin-0.40%
Profit Margin5.47%
ROE23.73%
ROA5.96%
Growth
Revenue Growth38.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF300.01M $
CapEx (TTM)242.59M $
FCF Margin32.95%
FCF Yield11.71%
Net Debt705.19M $
Net Debt/EBITDA-69.29
Balance Sheet
Debt/Equity2.07
Current Ratio0.93
Quick Ratio0.82
Book Value/Sh1.389 USD
Cash/Share3.605 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.85 USD
Upside (mean)-4.8%
Target Range23.00 USD – 42.00 USD
$23.00-4.8% to mean$42.00
# Analysts13
Ownership
Shares Out.224.94M
Float212.46M
Insiders5.63%
Institutions71.55%
Short Interest
Short Ratio4.1d
Short % Float32.06%
Short % Out.26.67%
Shares Short62.22M
Short (prev mo.)61.17M
Technical
SMA 5031.91 (+1.5%)
SMA 20028.94 (+11.9%)
Beta2.42
S&P 52W Chg18.16%
Avg Vol (30d)12.93M
Avg Vol (10d)14.51M
Technical Indicators
RSI (14)51.4
MACD-0.5919
MACD Signal-0.5967
MACD Hist.+0.0048
BB Upper33.80 USD
BB Middle29.83 USD
BB Lower25.86 USD
BB Width26.61%
ATR (14)2.359 USD
Vol Ratio (20d)1.41x